Rasagiline: A review of its use in the treatment of idiopathic parkinsons disease

Drugs

Volumn 72, Issue 5, 2012, Pages 643-669

  Hoy, Sheridan M ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Levodopa; Parkinsons disease; Pharmacokinetics; Pharmacology; Rasagiline

Indexed keywords

CASPASE; CIPROFLOXACIN; CYCLOBENZAPRINE; CYTOCHROME C; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 4A; DEXTROMETHORPHAN; DEXTROPROPOXYPHENE; ENTACAPONE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LEVODOPA; METHADONE; PETHIDINE; RASAGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; THEOPHYLLINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; TYRAMINE;

ACCIDENTAL INJURY; ADJUVANT THERAPY; ANOREXIA; ANXIETY; APOPTOSIS; AREA UNDER THE CURVE; ARTHRALGIA; ATAXIA; BACKACHE; CENTRAL NERVOUS SYSTEM TOXICITY; CLINICAL GLOBAL IMPRESSION SCALE; CONFUSION; CONSTIPATION; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSKINESIA; ELECTROCARDIOGRAM; EMBASE; ENZYME ACTIVATION; FALLING; FATIGUE; HALLUCINATION; HEADACHE; HUMAN; HYPERPYREXIA; HYPERSEXUALITY; HYPERTENSION; IDIOPATHIC DISEASE; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INSOMNIA; LIVER FAILURE; MEDLINE; MELANOMA; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; MITOCHONDRION SWELLING; MONOTHERAPY; NAUSEA AND VOMITING; NEUROPROTECTION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERIPHERAL EDEMA; PROTEIN SECRETION; PULSE RATE; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MELANOMA; SKIN SQUAMOUS CELL CARCINOMA; SOMNOLENCE; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; SYSTOLIC BLOOD PRESSURE; THERAPY DELAY; TOXICITY; TREATMENT DURATION; TREATMENT INDICATION; UNIFIED PARKINSON DISEASE RATING SCALE; WEIGHT REDUCTION; XEROSTOMIA;

ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; INDANS; LEVODOPA; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE;

EID: 84858778407     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11207560-000000000-00000     Document Type: Review

References (63)

1. Lees A. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging 2005; 22 (9): 731-40 (Pubitemid 41242117)
2. Brunton LL, Chabner BA, Knollmann BC. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill Medical, 2011
3. LeWitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008 Dec; 359 (23): 2468-76
4. Clarke CE. Parkinson's disease. BMJ 2007 Sep; 335 (7617): 441-5 (Pubitemid 47372651)
5. Hauser RA, Zesiewicz TA. Advances in the pharmacologic management of early Parkinson disease. Neurologist 2007 May; 13 (3): 126-32 (Pubitemid 46743079)
6. Elmer LW, Bertoni JM. The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy. Expert Opin Pharmacother 2008 Nov; 9 (16): 2759-72
7. Jenner P, Langston JW. Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. Mov Disord 2011 Nov; 26 (13): 2316-23
8. Siddiqui MA, Plosker GL. Rasagiline. Drugs Aging 2005; 22 (1): 83-91 (Pubitemid 40188907)
9. Oldfield V, Keating GM, Perry CM. Rasagiline: a review of its use in the management of Parkinson's disease. Drugs 2007; 67 (12): 1725-47 (Pubitemid 47263179)
10. Teva Pharma GmbH. Rasagiline (Azilect-): summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/000574/WC500030048.pdf [Accessed 2011 Apr 12]
11. Teva Neuroscience Inc. Azilect-(rasagiline mesylate) tablets for oral use: prescribing information [online]. Available from URL: http://www. accessdata.fda.gov/drugsatfda-docs/label/2009/ 021641s002s003s004s005s007s008s010lbl.pdf [Accessed 2011 Apr 12]
12. Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan] , a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001 Jan; 132 (2): 500-6 (Pubitemid 32142364)
13. Thébault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy 2004 Oct; 24 (10): 1295-305 (Pubitemid 39304992)
14. Rabey JM, Sagi I, Huberman M, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 2000 Nov-Dec; 23 (6): 324-30 (Pubitemid 32047014)
15. Freedman NM, Mishani E, Krausz Y, et al. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using 11C-L-deprenyl and PET. J Nucl Med 2005 Oct; 46 (10): 1618-24 (Pubitemid 46211585)
16. Goren T, Adar L, Sasson N, et al. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. J Clin Pharmacol 2010 Dec; 50 (12): 1420-8
17. Naoi M, Maruyama W. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Expert Rev Neurother 2009 Aug; 9 (8): 1233-50
18. Weinreb O, Bar-Am O, Amit T, et al. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 2004 Sep; 18 (12): 1471-3 (Pubitemid 39561618)
19. Weinreb O, Bar-Am O, Prosolovich K, et al. Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease? Antioxid Redox Signal 2011 Mar; 14 (5): 767-75
20. Teva Pharmaceutical Industries Ltd. Data on file. 2011 Dec
21. Perez-Lloret S, Rascol O. Safety of rasagiline for the treatment of Parkinson's disease. Expert Opin Drug Saf 2011 Jul; 10 (4): 633-43
22. Chen JJ, Panisett M, Rhyee S. Rasagiline and antidepressant use in patients with Parkinson's disease: assessing the occurrence of serotonin toxicity [abstract]. 2011 Annual Meeting of the American College of Clinical Pharmacy; 2011 Oct 16-19; Pittsburgh (PA)
23. Teva Pharmaceutical Industries Ltd. Investigation of the occurrence of serotonin toxicity in Parkinson's Disease (PD) patients treated concomitantly with rasagiline and antidepressants, using retrospective chart review [Clinical-Trials.gov identifier NCT00955604]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ [Accessed 2012 Jan 19]
24. Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther 2007 Sep; 29 (9): 1825-49 (Pubitemid 350212811)
25. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol 2002 Dec; 59 (12): 1937-43
26. Parkinson Study Group. A controlled, randomized, delayedstart study of rasagiline in early Parkinson disease. Arch Neurol 2004 Apr; 61 (4): 561-6
27. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62 (2): 241-8
28. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009 Sep; 361 (13): 1268-78. Plus supplementary material available from URL: http://www.nejm. org/[Accessed 2011 Mar 8]
29. Biglan KM, Schwid S, Eberly S, et al. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord 2006 May; 21 (5): 616-23 (Pubitemid 43840530)
30. Hauser RA, Lew MF, Hurtig HI, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009 Mar; 24 (4): 564-73
31. Lew MF, Hauser RA, Hurtig HI, et al. Long-term efficacy of rasagiline in early Parkinson's disease. Int J Neurosci 2010 Jun; 120 (6): 404-8
32. Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011 May; 10 (5): 415-23
33. Brown RG, Dittner A, Findley L, et al. The Parkinson fatigue scale. Parkinsonism Relat Disord 2005 Jan; 11 (1): 49-55 (Pubitemid 40037598)
34. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008 Nov; 23 (15): 2129-70
35. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005 Mar; 365 (9463): 947-54 (Pubitemid 41071428)
36. Stocchi F, Rabey JM. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease. Eur J Neurol 2011 Dec; 18 (12): 1373-8
37. Tolosa E, Stern MB. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease. Eur J Neurol 2012 Feb; 19 (2): 258-64
38. Reichmann H, Jost WH. Efficacy and tolerability of rasagiline in daily clinical use: a post-marketing observational study in patients with Parkinson's disease. Eur J Neurol 2010 Sep; 17 (9): 1164-71
39. Goetz CG, Schwid SR, Eberly SW, et al. Safety of rasagiline in elderly patients with Parkinson disease. Neurology 2006 May; 66 (9): 1427-9 (Pubitemid 43739656)
40. Elmer L, Schwid S, Eberly S, et al. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci 2006 Oct; 248 (1-2): 78-83 (Pubitemid 44647289)
41. Teva Pharmaceutical Industries Ltd. Teva announces Health Canada approves Azilect-(rasagiline) for Parkinson's disease [online]. Available from URL: http://www. tevapharm.com/en-US/Media/News/Pages/2006/1557352. aspx [Accessed 2012 Jan 31]
42. Teva Pharmaceutical Industries Ltd. Teva announces that Azilect-(rasagiline) is approved for marketing in Israel [online]. Available from URL: http://www.tevapharm. com/en-US/Media/News/Pages/2005/1557104.aspx [Accessed 2012 Jan 31]
43. Henchcliffe C, Severt WL. Disease modification in Parkinson's disease. Drugs Aging 2011; 28 (8): 605-15
44. Olanow CW, Kieburtz K. Defining disease-modifying therapies for PD: a road map for moving forward. Mov Disord 2010 Sep; 25 (12): 1774-9
45. National Institute for Health and Clinical Excellence. Parkinson's disease: diagnosis and management in primary and secondary care (NICE clinical guideline 35). London: NICE, 2006 [online]. Available from URL: http://www. nice.org.uk/nicemedia/live/10984/30088/30088.pdf [Accessed 2011 Jul 27]
46. OertelWH,BerardelliA, BloemBR, et al.Early (uncomplicated) Parkinson's disease. In: Gilhus NE, Barnes MP, Brainin M, editors. European handbook of neurological management. 2nd ed. Oxford: Wiley-Blackwell, 2011; 1: 217-36
47. Scottish Intercollegiate Guidelines Network. Diagnosis and pharmacological management of Parkinson's disease: a national clinical guideline (SIGN publication no. 113).Edinburgh: SIGN, 2010 Jan
48. Oertel WH, Berardelli A, Bloem BR, et al. Late (complicated) Parkinson's disease. In: Gilhus NE, Barnes MP, Brainin M, editors. European handbook of neurological management. 2nd ed. Oxford: Wiley-Blackwell, 2011; 1: 237-67
49. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson's disease. An evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002 Jan; 58 (1): 11-7 (Pubitemid 34041931)
50. Schapira AH. Treatment options in the modern management of Parkinson disease. Arch Neurol 2007 Aug; 64 (8): 1083-8 (Pubitemid 47258065)
51. Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice parameter: treatment of nonmotor symptoms of Parkinson disease. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010 Mar; 74 (11): 924-31
52. Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology 2010 Apr; 74 (14): 1143-8
53. Olanow CW, Rascol O. The delayed-start study in Parkinson disease: can't satisfy everyone [letter]. Neurology 2010 Apr; 74 (14): 1149-50
54. Ahlskog JE, Uitti RJ. Reply to Drs. Olanow and Rascol [letter]. Neurology 2010 Apr; 74 (14): 1151
55. Montgomery Jr EB. The delayed-start study in Parkinson disease: can't satisfy everyone. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? [letter]. Neurology 2010 Nov; 75 (21): 1943; author reply 1944-5
56. Schwarzschild MA. The delayed-start study in Parkinson disease: can't satisfy everyone. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? [letter]. Neurology 2010 Nov; 75 (21): 1943-4; author reply 1944-5
57. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003; 18 (7): 738-50
58. Teva Pharmaceutical Industries Ltd. ADAGIO follow up study: evaluation of the long-term effects of rasagiline in Parkinson's disease subjects [ClinicalTrials.gov identifier NCT00936676]. US National Institutes of Health. ClinicalTrials. gov [online]. Available from URL: http://clin icaltrials.gov/[Accessed 2012 Jan 27]
59. Haycox A, Armand C, Murteira S, et al. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation. Drugs Aging 2009; 26 (9): 791-801
60. Groenendaal H, Tarrants ML, Armand C. Treatment of advanced Parkinson's disease in the United States: a costutility model. Clin Drug Invest 2010; 30 (11): 789-98
61. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000 Oct 18; 284 (15): 1931-8
62. Hudry J, Rinne JO, Kerä nen T, et al. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland. Ann Pharmacother 2006 Apr; 40 (4): 651-7
63. Liu R, Gao X, Lu Y, et al. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011 Jun; 76 (23): 2002-9